{"id":63969,"date":"2026-03-20T08:20:24","date_gmt":"2026-03-20T08:20:24","guid":{"rendered":"https:\/\/ciaoup.it\/?p=63969"},"modified":"2026-03-20T08:20:24","modified_gmt":"2026-03-20T08:20:24","slug":"ribo-expands-beyond-the-liver-with-ribopepstar-enabling-targeted-sirna-delivery-to-multiple-organs","status":"publish","type":"post","link":"https:\/\/ciaoup.it\/?p=63969","title":{"rendered":"Ribo expands beyond the liver with RiboPepSTAR\u2122 – enabling targeted siRNA delivery to multiple organs"},"content":{"rendered":"

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE<\/p>\n

SUZHOU, China and M\u00d6LNDAL, Sweden, March 20, 2026 \/PRNewswire\/ — Suzhou Ribo Life Science Co., Ltd.\u00a0 (“Ribo” or “the Company”, Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.\u00a0\u00a0<\/p>\n

Following the success of RiboGalSTAR\u2122, which has supported seven clinical programs and major global partnerships valued over USD 6 billion, Ribo is now advancing its extra hepatic and multi-target platforms. The proprietary RiboPepSTAR\u2122 technology enables precise siRNA delivery to key organs beyond the liver, with promising preclinical data across several tissues.\u00a0\u00a0<\/p>\n

Kidney targeting\u00a0\u00a0<\/p>\n

Using RiboPepSTAR\u2122, preclinical studies demonstrate selective uptake in proximal tubular cells across models, and up to 80% target gene knockdown (KD) has been achieved, from rodents to NHPs. Physiological proof of concept was further validated in several disease models, such as type 2 diabetes model, showing robust kidney specific target-related biomarker reduction. Ribo’s first kidney-targeted drug has entered IND-enabling phase.\u00a0\u00a0<\/p>\n

Cardiac targeting\u00a0\u00a0<\/p>\n

A cardiac targeting conjugate resulted in sustained knockdown in heart using a mouse model. Minimal effects were observed in muscle and negligible activity in liver and kidney, confirming strong cardiac specificity.\u00a0\u00a0<\/p>\n

Adipose tissue targeting\u00a0\u00a0<\/p>\n

In NHPs, current delivery enabled potent and selective adipose targeting with 96% knockdown.\u00a0\u00a0<\/p>\n

Together, these results underscore RiboPepSTAR\u2122’s potential to unlock siRNA-based therapies for renal, cardiac and metabolic diseases.\u00a0\u00a0<\/p>\n

In parallel, Ribo is advancing its multi target siRNA platform, enabling a single molecule to silence two or more genes simultaneously. Ribo’s dual target siRNAs achieve knockdown levels comparable to single target molecules, enabling synergistic pathway modulation and enhanced therapeutic benefit with a single therapeutic entity.\u00a0\u00a0<\/p>\n

Ribo’s proprietary extra hepatic and multi targeting platforms open the door to best-in-class therapies across a broad range of disease areas – fully aligned with Ribo’s commitment to delivering next generation siRNA medicines to patients worldwide.\u00a0\u00a0<\/p>\n

Logo – https:\/\/mma.prnewswire.com\/media\/2804420\/logo_Ribolia_Logo.jpg
\n\u00a0<\/p>\n

View original content:https:\/\/www.prnewswire.co.uk\/news-releases\/ribo-expands-beyond-the-liver-with-ribopepstar–enabling-targeted-sirna-delivery-to-multiple-organs-302719624.html
\n\u00a0<\/p>\n

Copyright 2026 PR Newswire. All Rights Reserved.\u00a0<\/p>\n

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi<\/p>\n

—<\/p>\n

immediapress\/pr-newswire<\/p><\/p>\n

\n\t\t<\/a>\n\t\t<\/div>","protected":false},"excerpt":{"rendered":"

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE SUZHOU, China and M\u00d6LNDAL, Sweden, March 20, 2026 \/PRNewswire\/ —…<\/p>\n","protected":false},"author":3,"featured_media":63970,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[23],"class_list":["post-63969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-comunicati","tag-immediapress"],"_links":{"self":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/63969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63969"}],"version-history":[{"count":1,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/63969\/revisions"}],"predecessor-version":[{"id":63982,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/posts\/63969\/revisions\/63982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=\/wp\/v2\/media\/63970"}],"wp:attachment":[{"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ciaoup.it\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}